CMS Food Allergy Testing and Treatment Coverage Policy (NCD 266): What Billing Teams Need to Know

CMS updated NCD 266, the national coverage determination governing food allergy testing and treatment, with a modified policy effective March 12, 2026. This policy directly affects allergy, immunology, and primary care practices that bill Medicare for any food allergy diagnostic or therapeutic services. The core rule hasn't changed—sublingual, intracutaneous, and subcutaneous provocative and neutralization testing, along with neutralization therapy for food allergies, remain excluded from Medicare coverage—but the modification warrants a fresh review of your billing workflows to ensure nothing is slipping through.

What CMS NCD 266 Says About Food Allergy Testing Coverage

The Centers for Medicare & Medicaid Services has maintained this exclusion since October 31, 1988, when it was codified following a Final Notice published in the Federal Register on September 29, 1988. The policy is blunt: CMS determined that available clinical evidence does not demonstrate that these tests and therapies are effective, which is the foundational basis for exclusion under Medicare's medical necessity standards.

The excluded services under NCD 266 fall into two categories—testing and treatment:

Excluded Testing Methods:

• Sublingual provocative and neutralization testing for food allergies
• Intracutaneous provocative and neutralization testing for food allergies
• Subcutaneous provocative and neutralization testing for food allergies

Excluded Treatment:

• Neutralization therapy for food allergies (administered via any route covered under this NCD)

This is a broad exclusion. It doesn't carve out exceptions for specific patient populations, severity levels, or clinical scenarios. If a service falls into one of those categories and is billed to Medicare for a food allergy indication, CMS will not pay—full stop.

Why This CMS Policy Modification Matters to Revenue Cycle Teams

Even when the substantive coverage rule doesn't change, a policy modification from CMS signals that the agency has reviewed and re-affirmed the NCD's parameters. That matters for three reasons.

First, it resets the clock on billing team awareness. Staff turnover and payer policy fatigue mean that exclusions like this can quietly create claims leakage when providers inadvertently bill non-covered services without proper advance beneficiary notice (ABN) documentation.

Second, modifications can sometimes reflect updates to benefit category classifications, cross-references, or claims processing instructions—all of which affect how your clearinghouse and billing system route and adjudicate claims. If CMS has updated the cross-reference or claims processing guidance tied to NCD 266, your billing system configuration may need to reflect that.

Third, commercial payers frequently align their own food allergy testing policies with CMS NCDs. If you're managing a mixed Medicare/commercial payer book of business, this modification is a natural trigger to audit whether your commercial payer policies for the same services have also shifted.

CMS Coverage Criteria for Food Allergy Testing Under NCD 266

There are no covered indications under NCD 266. The policy establishes a categorical exclusion—not a coverage determination with medical necessity criteria that can be met under specific circumstances.

This distinguishes NCD 266 from many other coverage determinations, where certain CPT codes may be covered if selection criteria are met. Here, no pathway to Medicare coverage exists for the named services.

The applicable benefit category under which this NCD sits is Diagnostic Tests (other). This classification matters when your billing team is building claim edits, because services in this category are subject to specific claims processing rules that may differ from physician services or durable medical equipment.

Affected Codes

The policy does not list specific CPT, HCPCS, or ICD-10 codes. NCD 266 establishes a coverage exclusion by service description rather than by code enumeration.

Practical implication for billing teams: Because no codes are explicitly listed in the NCD, your team needs to identify the CPT codes your practice currently uses to bill food allergy provocative testing or neutralization therapy, then map those codes to the excluded service types described in NCD 266. Common code families to review include allergy testing procedures and immunotherapy administration codes—your billing or coding team should pull a utilization report filtered to Medicare patients and allergy-related procedure codes to identify any exposure.

Do not assume that the absence of a code list means the exclusion doesn't apply to a given CPT code. CMS's exclusion is written against the service, not the code.

Prior Authorization and Advance Beneficiary Notice Requirements

NCD 266 does not establish a prior authorization pathway for these services—because there is no coverage, there is nothing to authorize. However, prior authorization's absence doesn't reduce your compliance obligation.

Advance Beneficiary Notice (ABN) requirements apply. When a provider knows or expects that Medicare will not pay for a service, an ABN must be issued to the beneficiary before the service is rendered. This protects your practice's ability to bill the patient directly and ensures the patient has been appropriately informed of their financial responsibility.

For food allergy testing and neutralization therapy services, you should be issuing ABNs routinely for Medicare patients. If your front-desk or clinical workflow doesn't include a trigger for this, the NCD 266 modification is your prompt to fix it.

What Your Billing Team Should Do